Assessment of Blood Indices in Systemic Lupus Erythematosus
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorAssiut University
About this trial
This case-control study aims to explore the relationship between specific blood indices (lymphocyte-monocyte ratio, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammatory index) and disease activity in patients with systemic lupus erythematosus (SLE).
The study includes 70 SLE patients and 70 healthy controls, matched for age and gender, recruited from Assiut University Hospital.
Disease activity is assessed using the SLEDAI-2K score, and blood indices are analyzed to determine correlations with disease activity.
Eligibility criteria
Qualifiers
Patients aged 18 years or older diagnosed with SLE according to the 2019 ACR/EULAR classification criteria.
Healthy controls without any autoimmune diseases or significant comorbidities
Disqualifiers
• Patients with other autoimmune diseases (e.g., rheumatoid arthritis, Sjögren's syndrome).
Recent infections or acute inflammatory conditions.
Individuals with hematological disorders unrelated to SLE (e.g., leukemia, lymphoma).
Trial design
Treatments tested in this trial
- Not listed
Trial groups
70 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov